Weight Loss News
🇺🇸 FDAFDA breaking news and regulatory updates for BD, investors, and analysts
Showing 1–10 of 10 articles
GLP-1 usage statistics show broad uptake and mixed clinical signals
Pfizer's Danuglipron Hits Phase 2b Obesity Endpoint
Triple Hormone-Receptor Agonist Retatrutide for Obesity: Phase 3 Results and Market Impact
Pfizer's Berobenatide Obesity Drug: VESPER-3 Data and Competitive Outlook
Pfizer's Berobenatide: Monthly Obesity Drug Shows Promise in Phase 2b
US FDA Proposes New Regulations on Weight-Loss Drug Compounding
FDA Restricts Large-Scale Compounding of Weight Loss Drugs
Neurocrine Biosciences Begins Phase 1 Trial of NBIP-2118 for Obesity Treatment
Zealand Pharma's Survodutide Achieves 16.6% Weight Loss in Phase 3 Obesity Trial, Outperforming Current GLP-1 Therapies
FDA Approves Higher-Dose Wegovy 7.2mg for Weight Loss Under Priority Review Program